Aarti Pharmalabs Ltd (NSE: AARTIPHARM, BSE: 543748) is a Mumbai, Maharashtra-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹8,374 Cr, it ranks #650 by market cap among the 6,197 Indian listed companies on FinBizNet, and #4 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹996.00 (as of 16 Nov 2026), the share price is 2.3% below its 52-week high of ₹1,019.50 and 70.3% above its 52-week low of ₹585.00. The share price is up 15.4% over one year and up 14.2% over three months.
| Current Price | ₹996.00 |
|---|---|
| Market Cap | ₹8,374 Cr |
| NSE Symbol | AARTIPHARM |
| BSE Code | 543748 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 52.5 |
| Return on Equity | 8.49% |
| Return on Assets | 5.84% |
| 52-Week Range | ₹585.00 – ₹1,019.50 |
| 1-Year Price Change | +15.4% |
| 3-Month Price Change | +14.2% |
| Beta (1Y) | 0.43 |
| Dividend Yield | 0.40% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.aartipharmalabs.com |
| Revenue | ₹610 Cr |
|---|---|
| Net Profit | ₹71 Cr |
| Net Margin | 11.7% |
| EPS (Basic) | ₹7.88 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Aarti Pharmalabs Ltd reported revenue of ₹610 Cr in Q2 FY27, up 45.9% from ₹418 Cr in Q2 FY26 and up 13.9% from ₹536 Cr in Q1 FY27. It posted a net profit of ₹71 Cr for the quarter, against a net profit of ₹28 Cr in Q2 FY26 (up 156.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹386 Cr (Q1 FY26) to ₹610 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹610 Cr | ₹71 Cr | 11.7% |
| Q1 FY27 | ₹536 Cr | ₹76 Cr | 14.2% |
| Q4 FY26 | ₹583 Cr | ₹61 Cr | 10.5% |
| Q3 FY26 | ₹432 Cr | ₹48 Cr | 11.1% |
| Q2 FY26 | ₹418 Cr | ₹28 Cr | 6.7% |
| Q1 FY26 | ₹386 Cr | ₹50 Cr | 12.8% |
| Q4 FY25 | ₹564 Cr | ₹88 Cr | 15.7% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 39.66% of Aarti Pharmalabs Ltd's shares as of Sept 2026, against 42.88% in Sept 2025 (−3.22 percentage points). Delivery averaged 42.9% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalab
1. Pharmacuticals-This segment engages in the manufacturing and sale of pharmaceutical products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Pharmeceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,79,494 Cr | 73.6 | 16.98% | ₹4,979 Cr | +30.4% |
| Aether Industries Limited | ₹21,710 Cr | 101.8 | 9.81% | ₹347 Cr | +127.8% |
| Alivus Life Sciences Ltd | ₹17,862 Cr | 31.5 | 18.36% | ₹682 Cr | +64.0% |
| Aarti Pharmalabs Ltd | ₹8,374 Cr | 52.5 | 8.49% | ₹610 Cr | +15.4% |
| Solara Active Pharma Sciences Limited | ₹3,225 Cr | n/m | -0.63% | ₹417 Cr | +22.1% |
| Sai Parenteral's Limited | ₹2,235 Cr | 115.8 | 2.88% | ₹195 Cr | — |
| KRM Ayurveda Limited | ₹521 Cr | 25.9 | 17.54% | ₹32 Cr | — |
| Trident Lifeline Limited | ₹511 Cr | 26 | — | — | +37.6% |
| Infinium Pharmachem Limited | ₹436 Cr | 36.4 | 10.54% | — | +11.7% |
Listed by market capitalisation. Ratios are shown for context only.
Aarti Pharmalabs Ltd is trading at ₹996.00, with a market capitalisation of ₹8,374 Cr.
Aarti Pharmalabs Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Aarti Pharmalabs Ltd has a P/E of 52.5 and a return on equity of 8.49%.
Aarti Pharmalabs Ltd is listed on the NSE under the symbol AARTIPHARM and on the BSE under the scrip code 543748.
Aarti Pharmalabs Ltd's share price is up 15.4% over one year and up 14.2% over three months. Its 52-week range is ₹585.00 to ₹1,019.50.
In Q2 FY27, Aarti Pharmalabs Ltd reported revenue of ₹610 Cr and net profit of ₹71 Cr, with basic EPS of ₹7.88 (consolidated, parsed from the company's exchange filing).
Aarti Pharmalabs Ltd reported revenue of ₹610 Cr in Q2 FY27, up 45.9% from ₹418 Cr in Q2 FY26 and up 13.9% from ₹536 Cr in Q1 FY27.
Promoters held 39.66% of Aarti Pharmalabs Ltd's shares as of Sept 2026, against 42.88% in Sept 2025 (−3.22 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.